2024
Prostate cancer diagnosed and staged using UV-irradiated urine samples and a paper-based analytical device
BEZDEKOVA, Jaroslava, Mariana PLEVOVÁ, Lukas NEJDL, Mirek MACKA, Michal MASAŘÍK et. al.Základní údaje
Originální název
Prostate cancer diagnosed and staged using UV-irradiated urine samples and a paper-based analytical device
Autoři
BEZDEKOVA, Jaroslava (203 Česká republika), Mariana PLEVOVÁ (703 Slovensko), Lukas NEJDL (203 Česká republika), Mirek MACKA (203 Česká republika), Michal MASAŘÍK (203 Česká republika, domácí), Dalibor PACIK (203 Česká republika), Vojtech ADAM (203 Česká republika) a Marketa VACULOVICOVA (203 Česká republika, garant)
Vydání
Sensors and Actuators B: Chemical, LAUSANNE, Elsevier B.V. 2024, 0925-4005
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30204 Oncology
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 8.400 v roce 2022
Organizační jednotka
Lékařská fakulta
UT WoS
001143020700001
Klíčová slova anglicky
Molecularly imprinted polymers; UV -induced fluorescent clusters; UV -induced fluorescence fingerprinting
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 2. 2024 12:33, Mgr. Tereza Miškechová
Anotace
V originále
The early detection of prostate cancer (CaP), one of the most common cancers in males, improves treatment efficacy. However, current methods to detect CaP are limited by specificity and sensitivity or require an invasive and unpleasant procedure. Therefore, there is a need for a novel, fast, and noninvasive CaP detection method. This proof-of-concept study aimed to diagnose CaP from urine samples by detecting the UV-induced fluorescent clusters formed in situ that reflect a urine composition specific to CaP patients using fluorescence spectroscopy. The UV-induced clusters formed upon irradiation by UV light with a wavelength of 254 nm were detected at excitation and emission wavelengths of 400 nm and 460 nm. Fifteen patients with CaP were correctly distinguished from 5 controls. The different stages of CaP could be further determined using molecular imprinting technology. Additionally, a paper-based analytical device was developed that enabled the correct identification of stage I cancer patients by fluorescent spectroscopy detection and the naked eye. In conclusion, this novel, easyto-operate, point-of-care assay can enable early diagnosis of CaP with high accuracy and judgement of the disease stage. The simplicity, as well as versatility of the proposed method, will enable its application also to other diseases and disorders.